Repurposing auranofin for the treatment of cutaneous staphylococcal infections

International Journal of Antimicrobial Agents

Volumn 47, Issue 3, 2016, Pages 195-201

  Thangamani, Shankar ^a   Mohammad, Haroon ^a   Abushahba, Mostafa F N ^a,b   Sobreira, Tiago J P ^c   Seleem, Mohamed N ^a  

^a PURDUE UNIVERSITY   (United States)

^b Assiut University   (Egypt)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Auranofin; Inflammatory cytokines; Multidrug resistance; Repurposing; Topical antimicrobials

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AURANOFIN; BETA LACTAM DERIVATIVE; CLINDAMYCIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LINEZOLID; METICILLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PENICILLIN DERIVATIVE; PSEUDOMONIC ACID; RETAPAMULIN; SPECTINOMYCIN; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN; ANTIINFECTIVE AGENT; CCL2 PROTEIN, MOUSE; IL1B PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BIOFILM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INDICATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SKIN DEFECT; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT RESPONSE; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; WOUND INFECTION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG REPOSITIONING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCAL SKIN INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; AURANOFIN; BIOFILMS; CELL LINE; CHEMOKINE CCL2; DRUG REPOSITIONING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FUSIDIC ACID; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUPIROCIN; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84960204204     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.12.016     Document Type: Article

References (34)

1. M.E. Stryjewski, and H.F. Chambers Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus Clin Infect Dis 46 Suppl. 5 2008 S368 S377
2. S. Thangamani, W. Younis, and M.N. Seleem Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections Sci Rep 5 2015 11596
3. C.P. Montgomery, M.D. Daniels, F. Zhao, B. Spellberg, A.S. Chong, and R.S. Daum Local inflammation exacerbates the severity of Staphylococcus aureus skin infection PLoS ONE 8 2013 e69508
4. B. Fournier, and D.J. Philpott Recognition of Staphylococcus aureus by the innate immune system Clin Microbiol Rev 18 2005 521 540
5. A. del Rio, C. Cervera, A. Moreno, P. Moreillon, and J.M. Miro Patients at risk of complications of Staphylococcus aureus bloodstream infection Clin Infect Dis 48 Suppl. 4 2009 S246 S253
6. Y. Keynan, and E. Rubinstein Staphylococcus aureus bacteremia, risk factors, complications, and management Crit Care Clin 29 2013 547 562
7. J.C. McNeil, K.G. Hulten, S.L. Kaplan, and E.O. Mason Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children Antimicrob Agents Chemother 55 2011 2431 2433
8. D.J. Farrell, M. Castanheira, and I. Chopra Characterization of global patterns and the genetics of fusidic acid resistance Clin Infect Dis 52 Suppl. 7 2011 S487 S492
9. G.R. Corey, H. Jiang, and G. Moeck Dalbavancin or oritavancin for skin infections N Engl J Med 371 2014 1162 1163
10. A.F. Shorr, T.P. Lodise, G.R. Corey, C. De Anda, E. Fang, A.F. Das, and et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections Antimicrob Agents Chemother 59 2015 864 871
11. S. Thangamani, H. Mohammad, W. Younis, and M.N. Seleem Drug repurposing for the treatment of staphylococcal infections Curr Pharm Des 21 2015 2089 2100
12. C.R. Chong, and D.J. Sullivan Jr. New uses for old drugs Nature 448 2007 645 646
13. S. Thangamani, W. Younis, and M.N. Seleem Repurposing clinical molecule ebselen to combat drug resistant pathogens PLoS ONE 10 2015 e0133877
14. W. Younis, S. Thangamani, and M.N. Seleem Repurposing non-antimicrobial drugs and clinical molecules to treat bacterial infections Curr Pharm Des 21 2015 4106 4111
15. A. Debnath, D. Parsonage, R.M. Andrade, C. He, E.R. Cobo, K. Hirata, and et al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target Nat Med 18 2012 956 960
16. M.B. Harbut, C. Vilcheze, X.Z. Luo, M.E. Hensler, H. Guo, B.Y. Yang, and et al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis Proc Natl Acad Sci U S A 112 2015 4453 4458
17. S. Jackson-Rosario, D. Cowart, A. Myers, R. Tarrien, R.L. Levine, R.A. Scott, and et al. Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct J Biol Inorg Chem 14 2009 507 519
18. L. Aguinagalde, R. Díez-Martínez, J. Yuste, I. Royo, C. Gil, Í. Lasa, and et al. Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections J Antimicrob Chemother 70 2015 2608 2617
19. M.I. Cassetta, T. Marzo, S. Fallani, A. Novelli, and L. Messori Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections Biometals 27 2014 787 791
20. Y. Hokai, B. Jurkowicz, J. Fernández-Gallardo, N. Zakirkhodjaev, M. Sanaú, T.R. Muth, and et al. Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains J Inorg Biochem 138 2014 81 88
21. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth edition. Document M07-A9 2012 CLSI Wayne, PA
22. M.F. Mohamed, and M.N. Seleem Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection Drug Des Devel Ther 8 2014 1979 1983
23. S. Thangamani, H. Mohammad, M.F. Abushahba, M.I. Hamed, T.J. Sobreira, V.E. Hedrick, and et al. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent Sci Rep 5 2015 16407
24. S. Thangamani, W. Younis, and M.N. Seleem Repurposing celecoxib as a topical antimicrobial agent Front Microbiol 6 2015 750
25. J. Meletiadis, S. Pournaras, E. Roilides, and T.J. Walsh Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus Antimicrob Agents Chemother 54 2010 602 609
26. A.M. King, S.A. Reid-Yu, W. Wang, D.T. King, G. De Pascale, N.C. Strynadka, and et al. Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance Nature 510 2014 503 506
27. H. Mohammad, A.S. Mayhoub, M. Cushman, and M.N. Seleem Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant staphylococci J Antibiot (Tokyo) 68 2015 259 266
28. B.P. Conlon, E.S. Nakayasu, L.E. Fleck, M.D. LaFleur, V.M. Isabella, K. Coleman, and et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection Nature 503 2013 365 370
29. I. Jialal, E. Miguelino, S.C. Griffen, and S. Devaraj Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes J Clin Endocrinol Metab 92 2007 3136 3140
30. M.Y. Donath Targeting inflammation in the treatment of type 2 diabetes: time to start Nat Rev Drug Discov 13 2014 465 476
31. Y. Hu, and A.R. Coates Enhancement by novel anti-methicillin-resistant Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in vivo studies J Antimicrob Chemother 68 2013 374 384
32. L. Huang, T. Dai, Y. Xuan, G.P. Tegos, and M.R. Hamblin Synergistic combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: efficacy against bacterial burn infections Antimicrob Agents Chemother 55 2011 3432 3438
33. T.F. Mah, and G.A. O'Toole Mechanisms of biofilm resistance to antimicrobial agents Trends Microbiol 9 2001 34 39
34. C. Egsmose, B. Lund, G. Borg, H. Pettersson, E. Berg, U. Brodin, and et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study J Rheumatol 22 1995 2208 2213